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ABSTRACT 
CLINICAL NEAR-INFRARED SPECTROSCOPY INSTRUMENTATION: POSTURAL 
ORTHOSTATIC TACHYCARDIA SYNDROME STUDIES 
by 
Parvathi Kadamati 
The University of Wisconsin-Milwaukee, 2017 
Under the Supervision of Professor Mahsa Ranji 
 
Aims: Postural orthostatic tachycardia syndrome (POTS) is a type of chronic orthostatic 
intolerance, annually affecting around 500,000 young Americans. Symptoms of POTS include 
lightheadedness and persistent increase in heart rate with upright body posture [1-3]. It requires a 
medical diagnosis. Impaired cerebral oxygenation of patients with POTS has been reported [4]. 
The pathophysiology remains unclear, and research is needed to understand the underlying 
conditions that lead to POTS. The aim of this research is to design a medical device called 
Cytoximeter and apply it to conduct a study between POTS patients and healthy controls for 
objective monitoring and quantitative measurements.  
Introduction: A custom build near-infrared spectroscopy (NIRS) device called Cytoximeter was 
constructed to monitor the blood oxygenation and the redox behavior of intact tissue’s Cytochrome 
C Oxidase (CCO), in clinical and research setting, noninvasively. The presence of hemoglobin 
absorption leads to complex algorithm implementation to separate the signals of the hemoglobin 
and CCO. Today we have different kinds of oximetry available, which provide information about 
the hemoglobin levels. However, the hemoglobin signals can only provide information regarding 
the changes of oxygen in the tissue. Monitoring CCO may give us information about the metabolic 
status of the tissue and intracellular levels of oxygen [5]. CCO is the final acceptor in the electron 
transport chain (ETC) and is an essential part of aerobic or anaerobic metabolism [3, 6]. CCO 
reduces by taking electrons in ETC cycle. This enzyme accepts electrons and changes to reduced 
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state. The custom build optical device is designed to monitors the optical densities of the tissue by 
applying Beer-Lamberts law to monitor the change in concentration of these chemicals. This 
ability can give the NIRS many applications for research and clinical purposes. POTS is a clinical 
application for this device; a study was conducted to monitor the POTS patients and healthy control 
subjects to observe the difference in oxygenation levels between these two groups while 
undergoing the head up tilt table test. 
Methods: I measured and compared the difference in the changes in oxyhemoglobin and 
deoxyhemoglobin by applying this Cytoximeter to POTS patients and healthy controls while 
undergoing the heads-up tilt. The device uses the optimal source to detector separations to acquire 
the CCO signal and change in oxygenation of hemoglobin signals, which uses the six wavelengths 
near-infrared spectroscopic design. Validation of the device includes conducting the phantom 
studies and employing new experimental protocols. In the clinical setting, the device was applied 
to the muscles and brain tissue of the patients with POTS and Epilepsy under the standard care of 
neurological examiners. 
Results: The results showed significant differences in deoxyhemoglobin, oxygenation change and 
blood volume between the control subjects and POTS patients. We found that the arterial system 
is less compliant with the inability to receive additional blood volume in POTS patients. Results 
of the phantom studies that I conducted showed that the device was able to monitor the real-time 
changes in oxygenation of blood and the redox state of CCO.  
Conclusion: The custom build Cytoximeter successfully monitored the hemoglobin signal along 
with the CCO signal. The device provided an objective means of measuring and physiological 
findings in understanding the underlying reasons of POTS. Further work is required to determine 
whether the calf muscle activation of POTS patients is comparable to the healthy controls. 
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Near-infrared spectroscopy (NIRS) is commonly used to monitor hemodynamic responses 
by the measuring of the regional concentration changes of oxyhemoglobin (HbO2) and 
deoxyhemoglobin (Hb) using near-infrared light [1, 2, 6]. There is no risk or harm in applying 
NIRS to subjects for a long time. NIRS also has a high time-based resolution, portable, and low 
cost of equipment. These give NIRS many applications in clinical settings monitoring biological 
signals [7]. A variety of hemoglobin-based oximetry devices are available; however, clinicians 
currently cannot monitor the metabolic status of the tissue continuously and noninvasively [2, 8]. 
This research aims to monitor the cytochrome c oxidase (CCO) signal noninvasively by extending 
the optical techniques used in NIRS. CCO is an enzyme in the mitochondria which take place in 
electron transport chain (ETC) and hence can give information about the tissue metabolism [1, 2, 
6].  Light in the NIRS transparency window can easily penetrate deep into tissue and can be utilized 
to monitor the changes in the concentration of absorbing chemicals inside the tissue. The challenge 
of this work lies in the measuring tiny CCO signal along with a significant value of hemoglobin in 
the tissue using NIRS. 
Applying this clinical device to diseases like Postural orthostatic tachycardia syndrome 
(POTS) patients and Epileptic patients could provide an understanding to the clinicians about 
underlying reasons behind these disorders.  
1.1 My Contributions 
I developed and implemented a second-generation tissue Cytoximeter system based on the 
first-generation system developed in Biophotonics Lab. I then applied this method to study the 
difference in the change in Oxygenation of blood in POTS affected patients and healthy control 
subjects. In the procedure, the first step is to determine whether a healthy control subject has any 
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observable differences from the POTS patients. To show whether this Cytoximeter can detect the 
difference between POTS patients and healthy individuals. The results of this study between the 
POTS patients and healthy controls led to a journal article that is in the process of submission for 
publication and three poster presentations. One at the Institute of Electrical and Electronics 
Engineers (IEEE) Milwaukee, which was awarded the 3rd place in the graduate category, two in 
College of Engineering and Applied Science (CEAS) poster competition in 2016 and 2017.  
 I have redesigned the hardware of the Cytoximeter and replaced LEDs with LASER diodes 
of different wavelengths (705nm, 735nm, 750nm, 785nm, 808nm, and 850nm) and fiber optics 
system. The LASERs were employed as they have the tighter bandwidth and gives more collimated 
light. A new probe was designed using six different light sources with different wavelengths in the 
near-infrared window (650-1000nm). These wavelengths are chosen to be different from the 
previous incarnation of the probe as cross-talk between the chemicals was found in the results of 
the earlier version. I also introduced a fiber optic system which made the probe more efficient. The 
higher the number of wavelengths required for more advanced data processing protocol and 
filtering algorithm is needed. By using the new wavelengths and new data processing algorithms, 
the latest version of the Cytoximeter system can monitor the CCO along with the change in 
oxygenation of blood. In the making of second version Cytoximeter probe, I had to implement 
several novel approaches.  
 In this research project, I used different Computer-aided tools and programming languages. 
The device was controlled by a laptop running a LabVIEW program. The Virtual Instrument (VI) 
drives the device, displays and records the data in real time. I have designed a new LabVIEW 
experimental protocols. I have also made some changes in LabVIEW VI program to run the latest 
second version of cytoximeter. The recorded data was post-processed using a MATLAB 
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programming. I have made some changes to the MATLAB code, as the new version uses different 
wavelengths produced by LASER diodes as a light source. Post processing includes the extraction 
and separation of the CCO signal and hemoglobin signals. The graphing of representative signals. 
 As a validation of my probe, I have created a new experimental protocol using a force plate 
apparatus where the amount of force applied by the subject can be measured, and LabVIEW 
software can monitor the signal of the hemoglobin and CCO. Based on the previous phantom 
approach done by people in Biophotonics lab, I have implemented a similar experiment for 
validating the CCO signal for this new version of Cytoximeter. This ability could provide crucial 
diagnostic information by giving more information about metabolism than a standard blood 
oximetry device. The ability to detect metabolic activity status independent of blood oxygenation 
could help to determine different parameters of the disease quantitatively. 
 Since the study requires human subjects, I was certified by the Institutional Review Board 
(IRB). My responsibility includes editing and maintaining the consents, recruiting subjects and 
conducting every personal for the experiment. I was approved in the Institutional Animal Care and 
Use Committee (IACUC), and I am responsible for the IACUC protocol compliance as well. 
1.2 Tissue Optics 
 The tissue oximetry uses a continuous wave light source incident on the tissue. The incident 
light migrates through the tissue. The amount of light and angle of light traveling inside the tissue 
entirely depends on the absorbing and scattering coefficients of the tissue.  While considering the 
path of the incident light, one should assume the light traveling inside the tissue as light particles 
called photons. The photons travel through the tissue, and some of them are absorbed, and some 
diffuse reflected. An oximeter records change in the absorption along the path of photons through 
the tissue from source to detector [9]. These change in absorption are used to calculate 
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concentration by using Beer’s law. The path must be determined to find the depth of penetration 
and find the concentrations using Beer’s law. The determination of this path length is discussed in 
section 1.3 and its subsections. 
1.3 Principles of Near-Infrared Spectroscopy  
 NIRS utilizes wavelengths in the near-infrared window (650-1000 nm) to determine in vivo 
concentrations of chromophores. A useful application of NIRS is to monitor the health and 
function of a biological tissue both noninvasively and non-destructively. 
1.3.1 Oximetry 
 In the oximetry, near-infrared light is used to measure the changes in concentrations of 
oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) via the modified Beer-Lambert law. This law 
relates the amount of light absorbed to the length of the path that the light travels and the 
concentrations of chemicals in the tissue [9]. There are two types of oximeter configurations one 
is transmission oximetry and other is reflection oximetry. In reflective configurations, the light 
source and detectors are placed on the same side of the tissue and the light that is observed at the 
detector has been scattered back from the tissue [10]. In transmission oximeters, the light and 
detector are placed on opposite sides of a thin tissue typically a finger or earlobe [12, 21]. In general 
oximetry, a source of light is incident on the tissue and this light penetrates inside the tissue 
traveling in a phase like absorption and scattering or reflecting the detectors [9]. In both systems, 
measurement includes the amount of incident light and detected light at the detector. Both forms 
depend upon the Beer-Lambert law to calculate chromophore concentrations. The Beer-Lambert 
law is as follows: 
 
ln (
𝐼𝑜(𝜆)
𝐼(𝑡, 𝜆)
) =  ∑𝐿𝑖µλ𝑖𝛥𝐶𝑖 (1.1) 
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Where 𝐼(𝑡, 𝜆) is the light observed at the detector, Io(λ) is the expected or incident light at 
the detector, µ𝑖 is the absorption coefficient of a given chemical, 𝛥𝐶𝑖 is the change in concentration 
of a given chemical and L is the average path length that the photon takes from the source to the 
detector. This equation is valid for all wavelengths λ although the absorption coefficients will vary 
with wavelength according to the absorption spectra of chemical ‘i’ [11-13].  
These wavelengths are selected to give the highest signal to noise ratio (SNR). The 
oximeter typically uses wavelengths where the absorption spectra of the two species are very 
different [14]. Tissue oximeters often use two different wavelengths to determine the 
concentrations of both species of hemoglobin. Occasionally, oximeter uses a 3rd wavelength that 
corresponds to a point where the two wavelengths have very similar absorption coefficients [15]. 
This cross point is known as the isosbestic point and can be used to measure blood volume. 
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Figure 1.1 The absorption spectra for oxyhemoglobin (HbO2) and 
deoxyhemoglobin (Hb). The window highlighted is the transparency window in 
NIRS, which tissue has the lowest absorption and is nearly transparent to light. 
 
Figure 1.1 compares the absorption spectra of Hb and HbO2. When hemoglobin attaches 
or detaches from oxygen, it undergoes a small conformational change that causes a slight 
difference in absorption spectra.  
1.4 Cellular Respiration 
 Cellular respiration consists a large chain of reactions and metabolic activities that take 
place in the cell of the living organisms. The term includes both aerobic and anaerobic respiration, 
and the energy is generated during this process with oxygen and without oxygen respectively. If 
monitoring oxygen consumption, it is giving the information about the tissue’s aerobic cellular 
respiration; it does not include any information about anaerobic cellular metabolism. So, 
monitoring Cytochrome c oxidase may provide information on anaerobic metabolism [5, 6, 16].  
1.4.1 Hemoglobin 
 Hemoglobin is the oxygen transport protein in the red blood cells. As it carries oxygen, 
hemoglobin is involved in aerobic metabolism. This metabolism requires both oxygen and glucose 
to function. The oxygen that fuels the aerobic metabolism is the oxygen molecules that are 
separated from HbO2 particles. Once it gives the oxygen molecule, it changes to Hb. By monitoring 
changes in oxyhemoglobin and deoxyhemoglobin, the aerobic metabolism can be obtained [5, 16].  
1.4.2 Cytochrome C Oxidase 
 Cytochrome c oxidase (CCO) is transmembrane protein found in mitochondria of the cell. 
To understand the CCO NIRS signal, one must know the biochemistry behind it. CCO is the final 
acceptor ETC. The mitochondrial ETC mediates several different transfers, in the process 
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converting ADP to ATP. The change in ATP/ADP ratio provides usable energy to drive a wide 
variety of cellular processes [6, 17]. 
 As the final acceptor, CCO accepts the electrons at the end of ETC. When it does, it changes 
to reduced state. Then CCO oxidizes and uses the energy produced to pump the protons across the 
cell membrane. This process happens very quickly and slowly compared to ETC process as a 
whole. So, monitoring the CCO redox state by expecting more reduced state in metabolic activity 
and may give information of anaerobic metabolism [15, 18].  
1.5 Cytoximeter 
The cytoximeter is designed to obtain both the hemoglobin signal and CCO signal in the 
selected region of the tissue. The exact wavelengths must be chosen to estimate the amount of 
CCO in the tissue based on the absorption spectrum. Like hemoglobin changes whether associated 
or dissociated with an oxygen molecule, CCO undergoes a similar conformational change that 
affects its absorption spectra as the molecule reduces or oxidizes [19]. The same method that tracks 
the changes in HbO2 and Hb has been extended to monitor CCO by adding additional wavelengths 
to the detection device. By using all six wavelengths to find the concentrations of the four 
chemicals as noted in the figure. In the previous version of Cytoximeter different wavelengths 
were used and in results they found cross-talk between four chemicals- HbO2, Hb, reduced CCO 
(cyt red) and Oxidized CCO (cyt ox). So, to negate the cross-talk between these chemicals, a 
simulation of the wavelengths in the Infrared region (IR) of the absorption spectra was executed 
and new wavelengths were determined.  The optimum wavelengths determined were 705nm, 
735nm, 750nm, 785nm, 808nm, and 850nm. Figure 1.2 shows the absorption spectra for all four 
chemicals monitored in this study. 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Figure 1.2 The absorption spectra of the four chromophores in NIRS region. The 
six wavelengths that are used to identify these chemicals are highlighted by black 
lines. 
 
CCO will not account for most of the light absorption at any of these wavelengths [15]. 
Therefore, it is necessary to cancel out the effects of the hemoglobin on absorption before 
calculating the amount of cytochrome in the tissue. The following equation allows the extraction 
of the concentration of these four parameters:  
 10 
 
(
 
 
 
𝛥𝑂𝐷705
𝛥𝑂𝐷735
𝛥𝑂𝐷750
𝛥𝑂𝐷785
𝛥𝑂𝐷805
𝛥𝑂𝐷850)
 
 
 
= 𝐿
(
 
 
 
 
µ𝐶𝑦𝑡 𝑜𝑥(705𝑛𝑚) µ𝐶𝑦𝑡 𝑟𝑒𝑑(705𝑛𝑚) µ𝐻𝑏(705𝑛𝑚) µ𝐻𝑏𝑂2(705𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥(735𝑛𝑚) µ𝐶𝑦𝑡 𝑟𝑒𝑑(735𝑛𝑚) µ𝐻𝑏(735𝑛𝑚) µ𝐻𝑏𝑂2(735𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥(750𝑛𝑚) µ𝐶𝑦𝑡 𝑟𝑒𝑑(750𝑛𝑚) µ𝐻𝑏(750𝑛𝑚) µ𝐻𝑏𝑂2(750𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥(785𝑛𝑚) µ𝐶𝑦𝑡 𝑟𝑒𝑑(785𝑛𝑚) µ𝐻𝑏(785𝑛𝑚) µ𝐻𝑏𝑂2(785𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥(805𝑛𝑚) µ𝐶𝑦𝑡 𝑟𝑒𝑑(805𝑛𝑚) µ𝐻𝑏(805𝑛𝑚) µ𝐻𝑏𝑂2(805𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥(850𝑛𝑚) µ𝐶𝑦𝑡 𝑟𝑒𝑑(850𝑛𝑚) µ𝐻𝑏(850𝑛𝑚) µ𝐻𝑏𝑂2(850𝑛𝑚))
 
 
 
 
(
 
𝛥𝐶𝐶𝑦𝑡 𝑜𝑥
𝛥𝐶𝐶𝑦𝑡 𝑟𝑒𝑑
𝛥𝐶𝐻𝑏
𝛥𝐶𝐻𝑏𝑂2 )
  
(1.2) 
 
This equation is the form of a constrained regression problem. This problem can be solved 
by a Penrose pseudo-inverse to each side of the equation to be left with an estimate of the 
concentrations of the absorbing species on the right-hand side of the equation. While this method 
would work under ideal conditions, in practice there are several numerical problems often arise 
from approaching a problem such as this. By considering six wavelengths, a few co-linearity 
problems will be introduced into the regression matrix. All these issues were solved in the previous 
version of Cytoximeter [13]. 
1.6 Monte Carlo Simulations  
 The optimal distance between the source and detector depends on the structure of the tissue; 
the wavelengths used and desired depth of penetration. Increasing the source to detector separation 
results in greater depth of penetration [20]. But increasing the separation distance decreases the 
signal to noise ratio. A Monte Carlo method is applied to choose the optimal source-detector 
separation for the geometry of calf muscle oximetry. Monte Carlo is a stochastic process that 
models the path of photons through the tissue by repeated simulations [21, 22]. Every single 
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photon particle will undergo several scattering events in its propagation path from the incident 
point to the detection side as a step path as shown in the fig. 1.3.  This step size for single photon 
can be determined by equation 1.3, 
𝛥𝑠 =
−𝑙𝑛 (𝜉)
µ𝑡
=
−𝑙𝑛 (𝜉)
µ𝑠 + µ𝑎
 (1.3) 
Where 𝜉 is a random variable between 0 and 1, µ𝑎 is the absorption coefficient, and  µ𝑠 is the 
scattering coefficient. 
 
Figure 1.3 The path of a single photon particle traveling inside the tissue. After 
being scattered multiple times. The photon leaves at the same plane it was injected.  
 
By using Monte Carlo simulation, a computerized program is designed to process millions 
of photons while the undergoing absorbing and scattering at multiple layers of simulated tissue. 
The simulation was coded in a C++ environment, and image processing is performed with 
MATLAB by members in Biophotonics lab. The results of these simulations are displayed below. 
The tissue is modeled by 0.3 mm of the dermis, 1 mm of sub-dermis and a semi-infinite layer of 
the muscle beyond. Fig. 1.4 and 1.5 show Monte Carlo simulation results of light penetration in 
the tissue for 2 cm and 3 cm source to detector separation obtained by simulating the trajectories 
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of 108 photons through the calf and brain tissue. The densest parts of these simulations are graphed 
to give a sense of the average penetration of this optical path. The 2 cm source to detector 
separation provides a depth of penetration up to 1 cm. The 3 cm source to detector separation gives 
a depth of penetration up to 1.5 cm. 
 
 
Figure 1.4 Monte Carlo simulations for muscle geometry at both 2 cm and 3 cm 
source-detector separations. The densest parts of these simulations are shown on 
the bottom row to give a sense of the average penetration of these optical paths. 
 
1.7 POTS 
 Postural orthostatic tachycardia syndrome (POTS) is a syndrome caused by the postural 
changes in the body of the patient with POTS.  Symptoms of POTS include lightheadedness and 
persistent increase in heart rate (> 30 bpm in adults and > 40 bpm in children) with upright body 
posture [1-3].  Patients with POTS may experience many other symptoms such as fatigue, 
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sweating, tremor, anxiety, palpitation and exercise intolerance. Recumbency and assuming a 
supine position typically improve symptoms; however, these symptoms may lead to a high level 
of functional disability [23, 24]. A wide range of medications and treatment strategies are 
available, mainly emphasizing volume expansion and exercise [23].  
In this study, muscle oxygenation and metabolism of POTS patients were monitored to assess 
the effect of the postural change during Head-up tilt table (HUT). HUT is a standard test for 
patients with a potential POTS diagnosis to evaluate their response to postural change. During the 
HUT, blood pressure and heart rate are measured continuously [25]. However, subjects with an 
increase in heart rate that meets the diagnostic criteria for POTS have the same symptoms as those 
who do not [26].  Thus, other physiologic abnormalities may be present, such as changes in brain 
or muscle perfusion that might be detectable with a device such as NIRS during an absence of 
other vital sign changes.   
1.8 Epilepsy 
 Epilepsy may occur due to a genetic disorder or by attained brain injury, like trauma or 
stroke. Epileptic seizures have the disorder mostly in childhood neurologic condition and it a 
significant public health concern [8, 27]. The seizures cause poor coordination and disturbance of 
the different systems in the body and may even disable and interfere with the child’s ability to 
learn, can also lead to harmful effects in social and psychological function [14, 28, 29]. When a 
seizure occurs, a person has symptoms and experiences like abnormal behavior, symptoms, 
sensations, and sometimes even have loss of consciousness.  
 Epilepsy is treated with medicines, and if it is a severe case it is treated by surgery, devices, 
or dietary changes.  Epilepsy is a disorder in the nerve cell activity in the brain requires a medical 
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diagnosis and constant monitoring. NIRS technology has been used to monitor cerebral 
oxygenation and blood flow in children and adults in diverse conditions [30-33]. 
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2. Instrumentation and Design 
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The Cytoximeter was designed to monitor the blood hemoglobin signal along with the CCO 
signal.  The updated version of the probe has six different LASER sources and four photodetectors. 
LASERs were used in this new version as they have the tighter bandwidth and produce the more 
collimated output of light. This chapter gives the details of the device’s design and instrumentation 
involved. 
2.1 Hardware implementation 
 
 
Figure 2.1 Custom build NIRS Oximetry system consists of control box and probe, 
connected to a DAQ box and a laptop to run Lab VIEW software. 
  
Figure 2.1 shows the Cytoximeter schematic setup. The device is custom-made for this 
project that has a probe and a controlling box.  The probe contains the light sources and detectors 
that are used to measure the optical densities of the tissue. The probe was placed upon the surface 
of the muscle or skull. The control box contains circuitry for controlling the components like 
detectors and turning the LASER diodes on and off in sequence. The DAQ board acquire the data 
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and records on the laptop. The laptop also displayed the results of the CCO and hemoglobin data 
in real time.  
 
 
 
Figure 2.2 Cytoximeter system consists of DAQ board, control box, computer 
LabVIEW software and probe. 
 
2.1.1 Probe 
The probe head (figure 2.3) has the source and detectors, which are capable of producing 
and detecting six separate wavelengths of light. The light sources are LASER diodes. With 
different wavelengths 705, 735, 750, 785, 808 and 850nm (HL7001MG / HL7302MG / LT031MD 
/ L785P5 / L808P010 / L850P030, Thorlabs inc., NJ., USA). An optical fiber is attached to each 
LASER (figure 2.4), and all these six fibers are presented at the center of the probe head. The 
optical fibers are used as the LASER diodes diameter is big and there are assembled in an area 
around 3x2 mm. Which make the source to detector separation variable, i.e., a different LASER 
to detector distances. So, to center them at a single point on the tissue, optical fibers are the best 
choice. The construction of probe head with fiber is shown in figure 2.4. On the detection side, 
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four multi-pixel photon counters (MPPC’s) (Hamamatsu, S1133-14, Kyoto, Japan) were used on 
either side of the probe. These detectors were organized in two pairs to provide two different depths 
of penetration. The first pair of detectors were placed at a source-detector separation of 2 cm. The 
second pair of detectors were placed at a distance of 3 cm. As discussed in the previous chapter, 
the different source-detector separations produced different depths of penetration of the light. 
 
Figure 2.3 Probe head with four detectors and six different wavelengths LASER 
source (705/735/750/785/808 & 850nm) 
 
 
Figure 2.4 Introducing the fiber optics and Laser diodes. The figure shows the step 
by step construct process of the probe head. 
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2.1.2 Control Box 
The control box which controls the probe head to detector the signal from detectors and to 
power the sources. It contains the amplifiers for the signal that comes back from the detectors on 
the probe. It also circuitry that drives for LASERs. The control box talks with the DAQ board on 
the analog and digital channels of the DAQ board. The LASER’s were turned on and off by 
transistors in common emitter mode in the control box circuitry. These transistors were controlled 
and driven by the digital output from the DAQ board.  
2.2 Software Implementation 
The second version Cytoximeter software and implementation as the previous version. This 
section will give details for information LabVIEW program that helps to collect and monitor the 
data. 
2.2.1 LabVIEW 
The LabVIEW software operates the controlling parts of the Cytoximeter, like the DAQ 
board and circuit box. The software has a virtual instrument (VI) that accepts the analog input 
channels from the DAQ board for four detectors. Output a single eight-bit digital number to control 
which LASER to on and off based on configuration designed. The complete program was built 
with a large number of sub-Vis. Each sub-VI could perform its task and function that was necessary 
to the data analysis process. These sub-VIs was accessed through a top-level hub VI that also 
controlled the paths and names of the files generated by each sub VI. All of these VIs saves and 
store their data in a Technical Data Management Stream (TDMS) file format for post-processing. 
The DAQ board was programmed to continuously sample at each of the channels at a fixed 
rate. This rate of sampling was obtained based on the maximum response time of the circuitry. 
 20 
 
Similarly, the lights were turned on and off at a variable rate of up to 20Hz. That translates to a 
range of samples per wavelength and sampling rate for an entire six wavelengths cycle which can 
be changed depending on the results.  
2.2.2 Dark Current Correction 
The first VI in the series was the dark current correction VI. This VI get the amount of 
signal that was due to dark current on each of the channels. Dark current is an issue in every 
optoelectronic system which is caused by current leakage of the semiconductors in the detectors 
and by parasitic connections between the components in the system. As this process was not 
repeated before the experiment, subsequent VIs use the most recently obtained values. This test 
was done while the LASER’s were being switched on but the board was placed on a black media. 
This sub-VI is run before perform the main sub-VI, as it is essential to run while acquiring 
the small signals, as it may make a huge difference. The first VI in the series was the dark current 
correction VI. Dark current is a small little voltage that comes in the electronic system even when 
there is no light at the detectors. The dark current values were obtained to be stable over a long 
time and repeated tests. Therefore, it was assured that small changes in dark current were a minimal 
source of error in the system. 
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Figure 2.5 Dark current front panel window 
2.2.3 Ambient Pollution Correction 
To correct the ambient light pollution, a second sub-VI measured light seen by the probe 
after it had been applied to the subject. The LASER’s were not switched on during this procedure 
so that only the ambient light was recorded during this time. Even though the detectors were 
located on the underside of the probe when it was applied to the subject’s skin the detectors were 
sensitive enough to get the ambient light around the room with bright lighting. As the probe was 
designed for clinical use, it was considered that the lighting conditions in the room would not 
always be ideal. 
2.2.4 Baseline Acquisition 
To obtain optical densities baseline had to be processed and established.  Except for the 
sources, i.e., LASERs, we do not want any other light affecting the baseline, so the dark current 
and ambient light levels which we obtained before baseline get subtracted from the baseline values. 
That was done by the baseline sub-VI internally.  The baseline measurements were monitored until 
they were stable for at least a minute. The third VI obtains the baseline, during at the time where 
the LASER is not turned on or doing anything else to acquire the Hemoglobin signal and CCO 
signals. 
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Figure 2.6 Baseline front panel window 
2.2.6 Force Plate Protocol Baseline 
 In Force plate protocol, subject applies a force which is measured by the strain gauge. So 
this strain gauge instrumentation is connected to the LabVIEW software. In this, the subject needs 
to apply his/her maximum force at the starting of the experiment. So the LabVIEW software VI is 
designed to fix the maximum and then run the baseline VI to acquire the signals. This force plate 
baseline begins after the dark current VI. Once the maximum range of force is fixed in the VI, then 
baseline VI runs the LASERs and acquires the light levels. According to different protocol design, 
the subject may ask to apply certain of force (example 80%, 60% and 40% of max). While the 
baseline VI is in the process, when the subject applies certain force, it can record the value of the 
force applied. 
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Figure 2.7 Force Plate Protocol Baseline 
2.2.6 Acquisition VI 
The acquisition VI was used for reading the light levels of the light the incident on the 
subject body and then it will change or convert them to optical densities. Then it will record and 
display the real-time estimates. The OD values are used to estimate the changes in hemoglobin 
and CCO values. The baseline VI was the first VI for the experiment. This VI can also perform 
the functions by subtracting the dark current and ambient light from the light levels obtained and 
then applying the modified Beer-Lambert law to get the signal changes.  
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Figure 2.8 Acquisition front panel window 
2.2.7 Offline Data Analysis 
 This code analyzed the information by performing a data analysis technique known as 
Kalman filtering, which is discussed and implemented in the previous version [13]. When the  
Kalman filtering algorithm was applied and completed, estimates of the trends of HBO2, HB, 
Oxidized CCO, and Reduced CCO are obtained. In addition to these four signals, other three 
important signals were calculated, and these are blood volume, change in oxygenation (oxy) and 
CCO redox state. These equation mentioned below are assumed approximations that give the 
general trend of the oxy, CCO Redox State, and Blood volume.  The oxy, blood volume, and 
redox state were assumed estimations from the following equations. 
∆𝑜𝑥𝑦 = 𝛥𝐶𝐻𝑏𝑂2 − 𝛥𝐶𝐻𝑏 (2.1) 
∆𝐵𝑉 = 𝛥𝐶𝐻𝑏 + 𝛥𝐶𝐻𝑏𝑂2 (2.2) 
∆𝐶𝐶𝑂 𝑅𝑒𝑑𝑜𝑥 𝑆𝑡𝑎𝑡𝑒 =  𝛥𝑅𝑒𝑑𝑢𝑐𝑒𝑑 𝐶𝐶𝑂 −  𝛥𝑂𝑥𝑖𝑑𝑖𝑧𝑒𝑑 𝐶𝐶𝑂 (2.3) 
Reasonable expectations of oxy would represent the ratio of HbO2 to whole blood, Blood 
Volume would have the total blood in the tissue and redox state would represent the ratio of 
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reduced CCO to total CCO. As the device can only detect relative changes of these four chemicals 
and not the absolute values, which are impossible. So, the above equations are estimates of those 
chemicals. The data is collected and recorded in TDMS file format for post-processing. The TDMS 
file will open as excel format on a personal computer where the post analysis of the data is done. 
And then analyzed in MATLAB for processing and graphing of these chemicals.   
2.3 Research Protocols 
 To understand and correlate the results of the custom build probe, some research protocols 
are employed. These protocols aimed to undergo some exercises.  Designed a measuring apparatus 
using six-axis strain-gauge. 
2.3.1 Strain Gauge 
A six-axis strain gauge (Advanced Mechanical Technology, Inc., MC3A-1000, Watertown, MA) 
was utilized to measure the force that a subject applied to their foot Fig. 2.8. For the usage, applied 
the same settings and amplifier equipment that we used by the previous Biophotonics lab members.  
 
Figure 2.9 The strain gauge, arrows indicate the default coordinate system. 
2.3.2 Force Plate Apparatus 
A custom-built device was developed to hold the strain gage in all these arrangements. 
This device can be seen in figure 2.9. The employed protocol required 
the capacity to get the drive that subjects were able to apply by flexing their foot while in 
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standing, inclined and sitting stances. This made the strain gage a challenging 
matter since the device had to be able to be utilized in all these arrangements. 
The apparatus was built from machined metal parts and lumber. The device also included a 
foot restraint that is commercially accessible for utilize in paddling work out machines. 
 
Figure 2.10 The Force plate apparatus, designed to hold the strain gauge which 
measure the force applied by the subject. 
2.3.3 Pressure Cuff Validation 
 A different approach, casuing ischemia in the forearm muscle  to validate the hemoglobin 
signals changes monitored by Cytoximeter. That was based on published research which uses a  
charge-coupled device (CCD) based tissue spectroscopy [36]. The same experimental protocol 
was applied to an individual to cross-checked the hemoglobin results of the Cytoximeter. 
 The probe was applied to the forearm muscle, and a pressure cuff is attached to the arm. 
By applying pressure rapidly to cause oxygen desaturation in the forearm as shown in the figure 
2.11. 
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Figure 2.11 Pressure Cuff Protocol 
 
2.4 Phantom Validation 
2.4.1 Solid phantom 
An artifical tissue called as phantom has two phases i.e., solid and liquid phase. The solid 
phantom was made by using 1% by mass agarose-gel [34]. The liquid phase consists of intralipid 
as scattering material and India ink as absorbing the material. The ink was used as it has the 
absorbing properties which could mimic different tissues [35]. The fat emulsion called intralipid 
was added as scattering coefficient to the gel with excellent reliability [34, 35].  Cubbedo reported 
on trends on optical properties using these materials. The data from these trends were used to create 
several layers of the phantom that resembles different layers of the tissue. The ink has a non-
negligible contribution to scattering of the phantom to develop a more reliable phantom, 
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concentration of both Intralipid and India ink were extrapolated from writing that utilized a 
phantom that contained both [34, 36], that were used to change the optical properties of the gel. 
The concentration of both India ink and Intralipid are added to the phantom based on the 
type of tissue. Different types of tissues have a different kind of absorption and scattering 
coefficients.  
Tissue Reduced scattering 
coefficient (cm−1) 
Concentration of 
intralipid 
(% emulsion) 
Absorption 
Coefficient 
(cm−1) 
Concentration of 
India Ink by  
(% by volume)10−5 
Dermis 23 3.2 0.02 3.6 
Muscle 9.0 1.1 0.05 8.2 
Skull 30 4.3 0.02 3.6 
Brain 10 1.25 0.05 8.2 
 Table 2.1: Optical properties of the phantom and simulated tissue. 
 
In the construction of the artificial tissue called phantom, which is made by mixing the 
agarose with water and heated in a microwave and then it cools down into a solid clear material. 
Then based on the tissue absorption and scattering coefficients India ink and intralipid 
concentrations are added as a solution. Thus, a layered solid phantom is made and be shown in the 
fig.2.10. a). The second phantom mentioned liquid phantom is made to detect the changes in 
concentrations like CCO, blood concentrations. To this liquid phantom, this concentration is added 
based on the tissue. So, to monitor this change liquid phantom is made. The phantom was 
constructed in a plastic cell culture flask (VWR cell culture flask, Standard Line, 75ml). An 
agarose gel layer was embedded on one side of the flask while the remaining volume of the flask 
is left empty. The rest of the flask was filled with a DI water, Intralipid and India ink solution that 
resembles the deeper tissues optical properties. The two-phase phantom is shown in figure 2.10 b). 
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Figure 2.12 a) It is only a Solid phantom which is embedded and dried in the cell 
culture flask and stuck to the flask wall. b) Solid phantom filled with the liquid 
phase. 
 
2.4.2 Phantom Experiments 
 The two-phase phantoms were used to test and detect the performance of the probe by 
detecting the change in concentration of CCO bolus. Figure 2.13 shows the results of one of the 
phantom test conducted. The probe is applied to the phantom and monitored the data by adding 
hemoglobin and CCO at different intervals. To monitor the reduction in this chemical’s 
concentration, a reducing agent called Sodium Dithionite (Sigma-Aldrich, USA) is added. This 
experiment is done in a dark environment. The hemoglobin used was Ferrous hemoglobin from 
bovine blood (H2500, Sigma-Aldrich, USA). The cytochrome c oxidize chemical used for this 
study was prepared and test by MCW personal. The baseline was monitored without adding any 
of CCO or hemoglobin chemicals. In second interval, hemoglobin bolus is added where 
oxyhemoglobin signal showed an increase. In third interval, more hemoglobin bolus is added, 
oxyhemoglobin signal showed a step increase. Then in the next two interval CCO bolus added, 
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oxidized CCO showed rise and reduced CCO showed drop. And then a reduced by a reducing 
agent as sodium dithionite and monitored for around 10 minutes. Once the reducing agent came 
into action, slowly oxyhemoglobin and oxidized CCO decreased and reduced CCO increased. 
These results showed that the Cytoximeter device is able to monitor this chemical concentration 
changes. 
 
Figure 2.13 Phantom Results 
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3. Clinical Data 
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3.1 POTS Experimental Protocol 
The NIRS oximetry probe was placed on the right gastrocnemius. A gold standard 
Covidien oximetry probe (INVOS 5100B, Covidien/Medtronic, Minneapolis MN, USA) was 
placed on the left gastrocnemius to be used as a reference for comparison of the change in 
oxygenation measurements Fig 3.2.  
The subject is asked to lay on the tilt table, monitored for 10 minutes at 0 angle of the 
HUT as a baseline. And subject was taken to an angle of 70 and monitored for 30 minutes, and 
as a recovery for 10 minutes subject was reclined to 0 as shown in Fig 3.1. 
 
. 
Figure 3.1 The heads-up tilt table protocol, NIRS oximetry probe and Covidien 
probe are attached to the gastrocnemius muscle. Monitor at 00 and 700 angles of the 
tilt table for 10 minutes and 30 minutes respectively. 
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Figure 3.2 Image of the Tilt Table Protocol 
3.1.1 POTS Patients 
All the POTS patients were recruited under the approval of Institutional Review Board in 
Medical College of Wisconsin and Children’s Hospital of Wisconsin. All data were collected in 
Children’s Hospital of Wisconsin, Wauwatosa, WI.  As part of this exam, the patients were 
subjects to undergo heads up tilt table test. Twelve patients (age 8-18 years) underwent this 
protocol and were divided into 6 that completed the protocol who had POTS (rise in HR > 40 bpm 
in first 10 minutes) and 6 with syncope, and therefore had an incomplete tilt test and may or may 
not have had POTS.   
The tilt table setup is shown in figure 3.1. On one leg our probe was placed and on the other 
leg, a commercially available oximeter was placed on the calf. The two devices were run in parallel 
while the subject underwent a 70◦ tilt for 30 minutes. This test was designed to exacerbate 
symptoms that the subjects were experiencing. Because of this condition, n=6 of tests were ended 
early because the subjects either fainted or were in too much discomfort to continue. As a result, 
n=6 of the subjects’ data were counted in data processing for this experiment. 
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Subject 
type 
Mean 
age ± 
SD 
Gender Max 
HR 
first 
10’ of 
tilt 
Max 
HR 
During 
Tilt 
(bpm) 
Tilt 
duration 
(mins) 
POTS 14.1±1.9 1M, 5F 91 123 30 
Syncope 11.1±3 3M, 3F 99 118 10~20 
Healthy 
Controls 
21.1±2.6 2M, 4F 72 85 30 
 
Table 3.1: Subjects details include the health condition type, age, gender and heart 
rate before,during and after the tilt.  
 
3.1.1 Healthy Controls 
The 6 healthy control data were collected in the University of Wisconsin-Milwaukee. 
Healthy control subjects (age 18-24 years) were volunteered to this study. And they were 
consented and questioned before the procedure. That they could be on no medications and had no 
history of fainting, or lightheadedness with standing in the last year. The difference between the 6 
patients who completed the protocol and 6 healthy control subjects is considered.  
 
3.2 Epilepsy Experiment Protocol 
 All the Epilepsy patients were recruited at Children’s Hospital of Wisconsin; n=4 subjects 
were monitored while undergoing a standard of care neurological exam. All these patients were 
recorded that they had seizures in last 24 hours.  As part of this exam, they were subjected to attach 
the NIRS cytoximeter probe to the forehead as shown in the fig 3.3. And in addition to the 
cytoximeter, a NIRS probes from Hitachi (ETC 4000 NIRS, Hitachi, USA) were attached to the 
back of the head. This Hitachi probe only gives the hemoglobin changes. And this protocol is in 
progress of obtaining signals. 
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Figure 3.3 Epilepsy protocol, NIRS Cytoximeter is attached at forehead of the 
subject and Hitachi NIRS probes are attached at back of the head. 
.  
 
3.3 Clinical Data 
3.3.1 POTS and Healthy controls Clinical data 
 
 
Figure 3.4 Results of Tilt table test on healthy subjects n=6, showing hemodynamic 
changes. 
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3.3.1.1 Validation of device 
NIRS oximetry probe monitors the oxygenation change. Along with this NIRS probe, as a 
reference a different oximeter which is commercially available device in the market to monitor the 
oxygenation change (INVOS 5100B Covidien, USA). Figure 3.5 shows the correlation graph 
between the two probe’s oxygenation change. The data is shown for both the healthy controls and 
POTS patients at the baseline, 700 tilt and recovery. Regional oxygenation change parameter for 
Covidien Oximetry device is ‘percentage’ (%), whereas for NIRS probe device’s oxygenation 
change parameter is ‘concentration’(microMolar or M). 
 During the 70tilt, the data trend is similar for oxygenation change in both Covidien 
Oximetry device and NIRS probe device for healthy subjects and POTS patients. The value of R2 
closer to 1.0 shows the better fit of the regression line between Covidien probe and custom build 
NIRS oximetry probe.  
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Figure 3.5 Regional Oxygenation change correlation graph between Covidien 
probe and NIRS oximetry Probe results in POTS and healthy controls subjects 
during baseline, tilt at 700 and recovery. R2 on the graphs closer to 1.0 show the 
better fit of the regression line. 
 
3.3.1.2 Physiological findings 
Figure 3.6 shows average oxy-hemoglobin (ΔCHbO2) and deoxyhemoglobin (ΔCHb) data 
collected from the healthy control subjects and patients with POTS. The three segments show the 
change in the posture of the subject from 0 (baseline) to 70 (tilt) and back to 0 (recovery). 
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Oxy-hemoglobin decreases during the 70 tilt in healthy subjects, and Deoxy-hemoglobin 
increases during the same time. For POTS patients, the direction is similar, i.e. increase in deoxy-
hemoglobin and decrease in Oxy-hemoglobin but the rise in deoxy-hemoglobin concentration in 
POTS patients is significantly greater than the rise in healthy subjects Statistics are shown in Fig 
3.6.  
 
Figure 3.6 Data comparison between Healthy subjects (non-POTS) and POTS 
patients depicts changes in average oxy-hemoglobin (HbO2) and deoxy-
hemoglobin (Hb) concentrations on changing the position of the tilt table at 00, 700 
and 00 for 10 mins, 30 mins and 10 mins respectively.  
 
3.3.1.3 Statistical differences 
In Fig. 3.7, the statistical analysis, each bar represents the averages of the oxyhemoglobin, 
deoxyhemoglobin, change in oxygenation and blood volume for both groups POTS and healthy 
subjects during the 70 tilt. 
The Student’s two-tailed t-test (p<0.01) is applied to the values of the signals to test for 
significant differences. From the figure, the oxyhemoglobin did not show any difference, 
deoxyhemoglobin showed significant difference in POTS patients and healthy controls. Hb levels 
showed a significant difference between patient and healthy subjects which has a p-value. The 
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observed difference shows that deoxy-hemoglobin is significantly more in patients with POTS 
than in healthy controls.  
Oxygenation change in patient and healthy controls has shown a significant difference with 
p<0.01. The drop of change in oxygenation concentration in POTS patients is significantly greater 
than in healthy control subjects. Blood volume changes in patients with POTS is more than healthy 
controls.  
 
  
Figure 3.7 Statistical analyses for hemodynamic changes in healthy subjects and 
patients with POTS. Change in average oxy-hemoglobin, hemoglobin, change in 
oxygenation (oxygen saturation) and blood volume in control subjects during the 
700 tilt. Referring p-value is <0.01. 
 
3.3.2 Epilepsy Clinical data 
 
 Ambient light and baseline levels of the light were obtained after the application of the 
probe on the head. The results of the commercial Hitachi oximeter probes were used to verify the 
measurements made by the cytoximeter probe. Epileptic patients need constant monitoring which 
could be done by the cytoximeter device to show the blood oxygenation changes and metabolic 
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activity by the redox state of CCO. The process of monitoring is still in process, the results show 
the oxyhemoglobin and deoxyhemoglobin along with the CCO redox state. The patient had 
epileptic seizures in last 24 hours. The results were monitored when the patient is not having the 
seizures.  
 
Figure 3.5 Epilepsy representative monitored raw data 
 
  
3.4 Research Protocol result 
 This research protocol was employed in order to show the CCO redox state, 
oxyhemoglobin and deoxyhemoglobin changes with the muscular exercise effort.  
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3.4.1 Pressure Cuff Experiment 
 The results of pressure cuff forearm ischemia experiment are shown in Fig 3.9. A 5 minutes 
baseline is obtained and then rapidly pressure applied up to 240 mmHg for about 5 minutes in the 
cuff which is attached to the subject.  The recovery is done for 5 minutes.  
 The results showed the same trends as in ischemia results from the publication [37], 
increase in deoxyhemoglobin and decrease in oxyhemoglobin where rapid pressurizing caused 
ischemia in the forearm muscle. That shows the ability of the probe to detect hemoglobin changes. 
 
Figure 3.6 Pressure Cuff results  
3.4.2 Force Plate Experiment 
 The probe was attached to the calf muscle of the subject. The subjects were asked to place 
their foot on the apparatus and raise the heel to apply the force on the strain gauge in force 
measuring direction. This exercise was repeated at three intervals by a change in the applied force 
80%, 60% and 40% of their respective maximum which was set at starting of the protocol in 
LabVIEW software. The results of the cytoximeter data of one of the representative are seen in the 
figure. 
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The results show that, with an increased metabolic activity of the muscle, the CCO redox 
state increases at each level of exercise. The oxyhemoglobin decreases, due to increase in 
metabolic activity and consumption of oxygen. This gives an increase in deoxyhemoglobin. 
During the rest, the metabolic activity decreases so the trends of oxyhemoglobin, 
deoxyhemoglobin and CCO redox state were opposite to the exercise results. 
 
Figure 3.7 The results from a force plate experiment. As the subject apply force 
measured by strain gauge at 80%, 60% and 40% exercise levels. 
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Figure 3.8 The blood volume and change in oxygenation results of the force plate 
at different exercise levels. 
  
Figure 3.11: The decrease of oxygenation and increase in blood volume is shown during 
the exercise according to the range of metabolic activity. Thus, from the results, we see what we 
expect to see with range of metabolic activity on the 80%, 60% and 40% of maximum exercises. 
Conclusion and Discussion 
 The goal of these experiments was to detect the change in hemoglobin along with the 
changes in CCO signal. These results have shown the custom-built device can measure the redox 
state of CCO along with changes in hemoglobin. Such device will assess the health of the patients 
that need constant monitoring of the metabolic actives and change in oxygenation of the tissue. 
The tilt table tests demonstrated that the subjects are experiencing venous pooling during 
the tilt. The hemodynamic changes observed during the tilt suggests that subjects have experience 
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the venous pooling by effective change in their legs blood volume. The remarkable differences in 
the pattern of change in HbO2 and Hb may provide a new understanding of the underlying 
pathophysiology of POTS.  Healthy subjects show a sharp rise in HbO2 that is quickly halted 
within the first 2 minutes upright, while POTS patients take about 10 minutes to rise to the same 
level.  Thus, the slope of rising of HbO2 differs markedly between the 2 groups.  
 The force plate exercise has demonstrated that exercise levels effect on the amount of 
metabolic actives by redox state of CCO. And the Pressure cuff experiment showed the device 
could monitor the hemoglobin changes. 
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4. Conclusion and Future Work 
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4.1 Conclusion 
I have designed the second version of Cytoximeter which has Laser diodes as the source. 
This Cytoximeter could successfully monitor the hemoglobin signal along with CCO signal. 
Applied the cytoximeter to muscle in different protocols and acquired objective means of results 
according to the metabolic activity.  
Coming to the clinical setting, the cytoximeter was applied to POTS patient and healthy 
controls to obtain the significant difference between POTS affected subjects and controls, as well 
as produce new physiological findings. This study investigates the potential use of NIRS 
spectroscopy for the quantitative measurement of calf hemodynamics in POTS patients and healthy 
controls. The custom-built probe was applied to study the hemodynamics in the calf muscle of 
patients suffering from POTS during a change in posture with heads up tilt table. This could 
potentially help in determining whether tissue tonicity plays a role in the symptoms experienced 
by POTS patients. Such results could be used to quantitatively track the progress of a therapy in 
terms of changes in muscle oxygenation. Another application would be in POTS examinations, as 
a means of providing objective evidence of the degree of the syndrome. The cytoximeter can be 
used as a clinical tool to acquire muscle or brain oximetry data from patients suffering from POTS 
and Epileptic seizures. The results of that study showed the ability of NIRS and its applications in 
the clinical settings.   
 
4.2 Future Work 
In clinical near-infrared spectroscopy (NIRS), movements of the subject often cannot be 
controlled. That can cause significant step changes in the baselines measurements of attenuated 
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signals [7].  
The manual identification and correcting this motion artifact in NIRS data is time-
consuming and may even be useless because it may lose valuable data. Updating the NIRS device 
by an automated method for identifying and correcting motion artifacts. An accelerometer-based 
motion artifact can provide long term application of NIRS. 
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